

Paper No. \_\_\_\_\_  
Filed: August 3, 2015

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

LUPIN LTD. and LUPIN PHARMACEUTICALS INC.  
Petitioner

v.

SENJU PHARMACEUTICAL CO., LTD., BAUSCH & LOMB, INC., and  
BAUSCH & LOMB PHARMA HOLDINGS CORP.,  
Patent Owner

---

Case IPR2015-01099  
U.S. Patent 8,669,290

---

**PATENT OWNER'S EXHIBIT LIST**

Further to 37 C.F.R. § 42.63(e), Patent Owner Senju Pharmaceutical Co., Ltd., hereby submits a current listing of Senju Exhibits to counsel for Petitioner Lupin Ltd. and Lupin Pharmaceuticals Inc.

<b>Exhibits</b>	<b>Description</b>
Exhibit 2001	U.S. Patent No. 8,129,431 to Sawa <i>et al.</i> , “Aqueous Liquid Preparation Containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid.”
Exhibit 2002	Lupin’s Paragraph IV Notice Letter dated December 19, 2013.
Exhibit 2003	Lupin’s Paragraph IV Notice Letter dated May 13, 2014.
Exhibit 2004	Lupin’s Paragraph IV Notice Letter dated July 3, 2014.
Exhibit 2005	Lupin’s Paragraph IV Notice Letter dated December 17, 2014.
Exhibit 2006	Lupin’s Paragraph IV Notice Letter dated February 19, 2015.
Exhibit 2007	Complaint, <i>Senju Pharm. Co., Ltd. et al. v. Lupin, Ltd. et al.</i> , No. 14-cv-00667 (D.N.J. Jan. 31, 2014), ECF No. 1.
Exhibit 2008	Complaint, <i>Senju Pharm. Co., Ltd. et al. v. Lupin, Ltd. et al.</i> , No. 14-cv-04149 (D.N.J. June 26, 2014), ECF No. 1.
Exhibit 2009	Complaint, <i>Senju Pharm. Co., Ltd. et al. v. Lupin, Ltd. et al.</i> , No. 14-cv-05144 (D.N.J. Aug. 15, 2014), ECF No. 1.
Exhibit 2010	Complaint, <i>Senju Pharm. Co., Ltd. et al. v. Lupin, Ltd. et al.</i> , No. 15-cv-00335 (D.N.J. Jan. 16, 2015), ECF No. 1.
Exhibit 2011	Consolidated scheduling order, <i>Senju Pharm. Co., Ltd. et al. v. InnoPharma Licensing, Inc. et al.</i> , No. 14-cv-06893 (D.N.J. April 16, 2015), ECF No. 30.
Exhibit 2012	Amended scheduling order, <i>Senju Pharm. Co., Ltd. et al. v. Lupin, Ltd. et al.</i> , No. 14-cv-00667 (D.N.J. Feb. 27, 2015), ECF No. 63.
Exhibit 2013	U.S. Patent No. 5,630,793 to Rowe, “Aqueous Ophthalmic Sprays.”
Exhibit 2014	Press Release by Bausch + Lomb, dated April 8, 2013, entitled “Bausch + Lomb Receives FDA Approval for Prolensa™ (bromfenac ophthalmic solution) 0.07%.”
Exhibit 2015	InnoPharma’s Paragraph IV Notice Letter dated September 19, 2014.
Exhibit 2016	InnoPharma’s Paragraph IV Notice Letter dated October 30, 2014.

Exhibit 2017	InnoPharma's Paragraph IV Notice Letter dated March 27, 2015.
Exhibit 2018	InnoPharma's Paragraph IV Notice Letter dated June 12, 2015.
Exhibit 2019	Metrics' Paragraph IV Notice Letter dated June 26, 2014.
Exhibit 2020	Paddock's Paragraph IV Notice Letter dated December 15, 2014.
Exhibit 2021	Paddock's Paragraph IV Notice Letter dated January 20, 2015.
Exhibit 2022	Apotex's Paragraph IV Notice Letter dated December 10, 2014.
Exhibit 2023	Watson's Paragraph IV Notice Letter dated June 1, 2015.
Exhibit 2024	Masson et al., <i>Stabilisation of ionic drugs through complexation with non-ionic and ionic cyclodextrins</i> , 164 INT'L J. PHARMACEUTICS 45 (1998).
Exhibit 2025	Loftsson et al., <i>Pharmaceutical Applications of Cyclodextrins</i> , 85 J. PHARMACEUTICAL SCIENCES 1017 (1996).
Exhibit 2026	HSBC Global Research Lupin Company Report, Feb. 3, 2014, <a href="http://www.lupin.com/pdf/14/20140203%20-%20Lupin%203QFY14%20-%20HSBC.pdf">http://www.lupin.com/pdf/14/20140203%20-%20Lupin%203QFY14%20-%20HSBC.pdf</a>
Exhibit 2027	Consent judgment, <i>Senju Pharm. Co., Ltd. et al. v. Apotex Inc. et al.</i> , No. 15-cv-00336 (D.N.J. May 18, 2015), ECF No. 26.
Exhibit 2028	Consent judgment, <i>Senju Pharm. Co., Ltd. et al. v. Paddock Labs., LLC et al.</i> , No. 15-cv-00337 (D.N.J. June 5, 2015), ECF No. 33.
Exhibit 2029	Consent judgment, <i>Senju Pharm. Co., Ltd. et al. v. Metrics, Inc. et al.</i> , No. 14-cv-03962 (D.N.J. July 1, 2015), ECF No. 108.
Exhibit 2030	U.S. Patent No. 5,856,345 to Doi et al., "Method for Stabilizing Pranoprofen and Stable Liquid Preparation of Pranoprofen."
Exhibit 2031	Drugs@FDA, Listing of FDA-approved bromfenac ophthalmic solution 0.09% products, <a href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&amp;DrugName=BROMFENAC%20SO DIUM">http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&amp;DrugName=BROMFENAC%20SO DIUM</a> .
Exhibit 2032	Sheryl Gay Stolberg, <i>New Painkiller is Withdrawn After 4 Deaths</i> , N.Y. TIMES, Jun. 23, 1998.
Exhibit 2033	Baklayan et al., <i>The ocular distribution of 14C-labeled bromfenac ophthalmic solution 0.07% in a rabbit model</i> , CLINICAL OPHTHALMOLOGY 1717 (2014).
Exhibit 2034	Schott, <i>Effect of inorganic additives on solutions of nonionic surfactants – XVI. Limiting cloud points of highly polyoxyethylated surfactants</i> , 186 COLLOIDS AND SURFACES A: PHYSICOCHEMICAL

	AND ENGINEERING ASPECTS 129 (2001).
Exhibit 2035	European Patent No. 0274870 to Story, M., et al., "Micelles containing a non-steroidal antiinflammatory compound" (filed December 12, 1987; issued July 7, 1988).
Exhibit 2036	Reddy, Indra K., <i>Ocular Therapeutics and Drug Delivery: A Multi-Disciplinary Approach</i> , 42-43, 390 (1996).
Exhibit 2037	Declaration of Uday B. Kompella in Support of Plaintiffs' Proposed Claim Constructions, <i>Insite Vision Inc. et al. v. Sandoz Inc. et al.</i> , No. 11-cv-03080, 2012 WL 8667473 (D.N.J. April 12, 2012).

Respectfully submitted,

Dated: August 3, 2015

By: /Bryan C. Diner/

Bryan C. Diner, Lead Counsel

Reg. No. 32,409

M. Andrew Holtman, Back-up Counsel

Reg. No. 53,032

Justin J. Hasford, Back-up Counsel

Reg. No. 62,180

Joshua L. Goldberg, Back-up Counsel

Reg. No. 59,369

Finnegan, Henderson, Farabow, Garrett  
& Dunner, L.L.P.

901 New York Ave. NW

Washington, DC 20001-4413

(202) 408-4000

*Counsel for Patent Owner*

**CERTIFICATE OF SERVICE**

The undersigned hereby certifies that a copy of the foregoing **Patent Owner's Exhibit List and Exhibits 2001 through 2037** were served on August 3, 2015, via email directed to counsel of record for the Petitioner at the following:

Deborah Yellin  
DYellin@crowell.com

Jonathan Lindsay  
JLindsay@crowell.com

Date: August 3, 2015

/Lisa C. Hines/

Lisa C. Hines  
Litigation Clerk

Finnegan, Henderson, Farabow, Garrett &  
Dunner, LLP